Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 4Withdrawn 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × siltuximab × Clear all
NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡